EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastomaConsensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trialsMGMT gene silencing and benefit from temozolomide in glioblastoma.ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.Radiotherapy plus concomitant and adjuvant temozolomide for glioblastomaImmunotherapy response assessment in neuro-oncology: a report of the RANO working groupExpress and protect yourself: the potential role of HLA-G on muscle cells and in inflammatory myopathiesExpression of the B7-related molecule ICOSL by human glioma cells in vitro and in vivoHuman malignant glioma cells express semaphorins and their receptors, neuropilins and plexinsAn endogenous tumour-promoting ligand of the human aryl hydrocarbon receptorPhosphoglycerate kinase 1 a promoting enzyme for peritoneal dissemination in gastric cancerThe topoisomerase II inhibitor, genistein, induces G2/M arrest and apoptosis in human malignant glioma cell linesMonocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomasPrognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastomaThe topoisomerase II inhibitor, genistein, induces G2/M arrest and apoptosis in human malignant glioma cell linesAcid sphingomyelinase–ceramide system mediates effects of antidepressant drugsComputer-assisted quantification of motile and invasive capabilities of cancer cells.Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients.Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.[Gliomas – What I Have to Know in ten Questions].Adenoviral natural born killer gene therapy for malignant glioma.Low molecular weight heparin for deep vein thrombosis in glioma patients.Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.Prevalence of potential sports-associated risk factors in Swiss amyotrophic lateral sclerosis patients.Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.ERGO: a pilot study of ketogenic diet in recurrent glioblastoma.Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence.Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.Defective p53 antiangiogenic signaling in glioblastoma.Monitoring the glioma tropism of bone marrow-derived progenitor cells by 2-photon laser scanning microscopy and positron emission tomographyPatients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape.mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression.Antiangiogenic therapy for glioblastoma: current status and future prospects.Mechanisms of apoptosis in central nervous system tumors: application to theory.Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide.Long-term survival with glioblastoma multiforme.
P50
Q24338526-0DB89F2F-5600-4993-B825-8405345DE9ADQ26801351-B20CF055-16A9-4D54-8A26-8D71216D08A8Q27824832-9AC2BD31-03C7-401C-A82D-4E081D5D979BQ27852494-4FE48C90-02BF-4D6E-8781-82330A4CADD3Q27860910-20A09482-1EDC-442E-87E6-DB9C9B7D3E30Q28083009-9E7D9240-6A3C-4840-857B-C21FC0D01C34Q28182144-FCA81570-60C1-416E-AC0F-94277987DCB1Q28182325-060A0D5A-F0B9-4EDE-B2AF-8B1D2B36D3BDQ28202573-4623AEB4-E27A-41CC-A67C-91BB0529A437Q28249782-763E837D-AE9F-4882-B44F-FFF02BEDFFC0Q28255495-D8AA38CE-2BEB-4AA4-B03E-CED9751967BCQ28273510-B12EB152-BD85-4055-B80A-31B842CB68E5Q28564777-635B246A-ECD5-423C-B7A8-005AB08963E5Q28731328-23084E4C-1059-44E4-999C-10A9ECDC9B15Q29012878-A49784C3-2DD4-42BB-B944-6784E4D76627Q29042551-F3948A9D-AEA8-46D3-B74F-CCAD5DE32B02Q30669870-4FFB1147-6EEF-4357-A5CB-230B557C1261Q30801851-DCE7CC77-BD16-45AB-93FA-701DA0A7CA22Q30836702-90852D2A-6D43-4A9B-B6CE-356A50C4DF41Q31058918-2D8F1F52-BA88-4293-9A87-E08D23E02DB3Q33188372-0710EC4E-DB3A-4561-BBF2-7CF187D8C979Q33344731-539CC6FE-FB1F-49F3-B8CF-EB6C97B06286Q33401179-7A905549-A2C6-44E7-AC93-4FB2A61D16C3Q33417361-8FDE83B4-16DB-4150-A54D-638FEA2DD85BQ33562103-28A353A8-58E6-41B1-96C7-0B77E0A32842Q33710967-0B6BB9C8-D6E5-4EAC-81B4-31BB32EAF0ADQ33711322-0C827DFD-F133-4180-9BD6-B4AA0F7C6908Q33778107-67C280FF-3C63-42B3-98D0-EB6F45BB0086Q33807228-FAA3471F-29B2-4B4A-916F-51B31D745041Q34113523-3D375DAF-46E6-49AD-A5E2-FD928E229B06Q34133118-D6C682DE-E788-4DBE-BAB2-A5D50D956D6EQ34148786-5ACAEFAA-4D97-4806-99A7-811110D32CB5Q34150635-B288DB34-974B-40D2-9DD2-A45B0DB896F3Q34365811-FABFD697-8F7E-426E-85E6-6E913952DEE3Q34394233-2B2C430B-65B3-448F-B734-E8784A865C47Q34398926-CE162901-E17B-44EC-9A3D-F723D64016E3Q34523319-EC5C517C-72C4-4126-BB59-21DA45465002Q34590759-713956C7-71B8-4FFA-BB67-D843B34F0273Q34604010-32F85F0B-85C0-4267-933B-D2DAA1248B72Q34676734-C7DAD7AC-BB1E-4E0E-AF46-4242314C46CB
P50
description
Duits arts
@nl
German physician
@en
German physician
@en-ca
German physician
@en-gb
Saksamaa arst
@et
deutscher Mediziner und Hochschullehrer
@de
dochtúir Gearmánach
@ga
fisikawan asal Jerman
@id
medic german
@ro
medico tedesco
@it
name
Michael Weller
@ast
Michael Weller
@ca
Michael Weller
@da
Michael Weller
@de
Michael Weller
@en
Michael Weller
@es
Michael Weller
@fr
Michael Weller
@nds
Michael Weller
@nl
Michael Weller
@pt
type
label
Michael Weller
@ast
Michael Weller
@ca
Michael Weller
@da
Michael Weller
@de
Michael Weller
@en
Michael Weller
@es
Michael Weller
@fr
Michael Weller
@nds
Michael Weller
@nl
Michael Weller
@pt
prefLabel
Michael Weller
@ast
Michael Weller
@ca
Michael Weller
@da
Michael Weller
@de
Michael Weller
@en
Michael Weller
@es
Michael Weller
@fr
Michael Weller
@nds
Michael Weller
@nl
Michael Weller
@pt
P214
P227
P244
P269
P106
P1207
n2008081507
P1368
P1412
P1559
Michael Weller
@de
P19
P21
P213
0000 0001 0866 191X
P214
P227
P244
n2015190664
P269
P31
P496
0000-0002-1748-174X
P569
1962-08-29T00:00:00Z